SIGLANA Trademark

Trademark Overview

On Friday, March 29, 2019, a trademark application was filed for SIGLANA with the United States Patent and Trademark Office. The USPTO has given the SIGLANA trademark a serial number of 88363288. The federal status of this trademark filing is REGISTERED as of Tuesday, August 25, 2020. This trademark is owned by Glaxo Group Limited. The SIGLANA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
siglana

General Information

Serial Number88363288
Word MarkSIGLANA
Filing DateFriday, March 29, 2019
Status700 - REGISTERED
Status DateTuesday, August 25, 2020
Registration Number6133178
Registration DateTuesday, August 25, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 9, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, April 17, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressStevenage SG12NY
GB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB

Trademark Events

Event DateEvent Description
Friday, June 14, 2019NON-FINAL ACTION WRITTEN
Tuesday, April 2, 2019NEW APPLICATION ENTERED
Wednesday, April 17, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, June 10, 2019ASSIGNED TO EXAMINER
Friday, June 14, 2019NON-FINAL ACTION E-MAILED
Friday, June 14, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, December 12, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 12, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, December 12, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 30, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, March 20, 2020ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Thursday, March 26, 2020PREVIOUS ALLOWANCE COUNT WITHDRAWN
Wednesday, January 15, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 4, 2020PUBLISHED FOR OPPOSITION
Tuesday, February 4, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, March 26, 2020NON-FINAL ACTION WRITTEN
Thursday, March 26, 2020NON-FINAL ACTION WRITTEN
Thursday, March 26, 2020NON-FINAL ACTION WRITTEN
Thursday, March 26, 2020NON-FINAL ACTION WRITTEN
Wednesday, April 8, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 8, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 9, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 30, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 20, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 9, 2020PUBLISHED FOR OPPOSITION
Tuesday, June 9, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 25, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, November 8, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 6, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, March 26, 2020NON-FINAL ACTION WRITTEN
Thursday, March 26, 2020NON-FINAL ACTION E-MAILED
Thursday, March 26, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 8, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, November 8, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 6, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 6, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 6, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 6, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, August 25, 2025COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

siglana pharmaceutical treatment disorders preparations substances diseases ophthalmic respiratory hepatological oncological